

| | | | | | | | | |
|--|----|--|------------------|------------------------------------|-------|--------------------------|------------------------------|----|
| SPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office | | | | Attorney Docket No. 351044-0012 | | Serial No. 10/612,648 | | |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | | | Applicant(s): Clouatre | | | | |
| | | | | Filing Date: July 2, 2003 | | Group: 1614 | | |
| U.S. PATENT DOCUMENTS | | | | | | | | |
| Examiner Initial | | Patent No. | Date | Name | Class | Subclass | Filing Date (if appropriate) | |
| Z.F. | A1 | 6,355,265 | 12 March 2002 | Ream, et al. | A61K | 9/68 | 23 February 2000 | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | |
| Examiner Initial | | Document No. | Publication Date | Country | Class | Subclass | Translation | |
| | | | | | | | YES | NO |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | | |
| Z.F. | C1 | International Search Report for PCT/US04/21541 | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | | |
| Zuhk Fay | | | | 5/9/06 | | | | |
| <small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.</small> | | | | | | | | |

| FORM PTO-1449 (Substitute) | | | | ATTY. DOCKET NO. | | SERIAL NO. | |
|--|----|---------------------|---------|-----------------------------|-------|------------|-------------------------------|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | APPLICANT CLOUATRE | | | |
| | | | | FILING DATE July 2, 2003 | | GROUP | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| ZF | AA | 20030119913 | 06/2003 | Ohia, et al. | 514 | 574 | |
| | AB | 20020187943 | 12/2002 | Majeed, et al. | 514 | 27 | |
| | AC | 6,476,071 | 11/2002 | Clouatre, et al. | 514 | 557 | |
| | AD | 6,221,901 | 04/2001 | Shrivastava, et al. | 514 | 458 | |
| | AE | 5,914,326 | 06/1999 | McCarty, et al. | 514 | 188 | |
| | AF | 5,783,603 | 07/1998 | Majeed, et al. | 514 | 574 | |
| | AG | 5,656,314 | 08/1997 | Moffett, et al. | 426 | 271 | |
| | AH | 3,993,668 | 11/1976 | Guthrie, et al. | 260 | 343.6 | |
| | AI | 3,919,254 | 11/1975 | Guthrie, et al. | 260 | 343.6 | |
| | AJ | 3,767,678 | 10/1973 | Guthrie, et al. | 260 | 343.6 | |
| ZF | AK | 3,764,692 | 10/1973 | Lowenstein | 424 | 279 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| ZF | AL | WO 02/078616 | 10/2002 | Ohia, et al. | | | |
| ZF | AM | WO 02/14477 | 02/2002 | Majeed, et al. | | | |
| | AN | | | | | | |
| | AO | | | | | | |
| | AP | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Portraits, Pages, Etc.) | | | | | | | |
| | AR | SEE ATTACHED SHEETS | | | | | |
| | AS | | | | | | |
| | AT | | | | | | |
| EXAMINER John F. Fay | | | | DATE CONSIDERED 5/19/06 | | | |
| * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

LIST OF PRIOR ART CITED BY APPLICANT

Sheet 2 of 3

Dallas L. Clouatre

(-)-HYDROXYCITRIC ACID FOR CONTROLLING INFLAMMATION

July 2, 2003

OTHER PRIOR ART

2.F Bruunsgaard H, et al. Long-term combined supplementations with alpha-tocopherol and vitamin C have no detectable anti-inflammatory effects in healthy men. J Nutr. 2003 Apr;133(4):1170-3.

Cloez-Tayarani I, et al. Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine(2A) receptors. Int Immunol. 2003 Feb;15(2):233-40.

Festa A, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000 Jul 4;102(1):42-7.

Harbuz MS, et al. Alteration of central serotonin modifies onset and severity of adjuvant-induced arthritis in the rat. Br J Rheumatol. 1998 Oct;37(10):1077-83.

Koenig W. Inflammation and coronary heart disease: an overview. Cardiol Rev. 2001 Jan-Feb;9(1):31-5.

McCarty MF. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. Medical Hypotheses 1994;42:215-225.

Ohia SE, et al. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). Mol Cell Biochem. 2002 Sep;238(1-2):89-103.

Pichler R, et al. Pro-inflammatory role of serotonin and interleukin-6 in arthritis and spondyloarthropathies--measurement of disease activity by bone scan and effect of steroids. Scand J Rheumatol. 2002;31(1):41-3.

Staels B, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR α but not by PPAR γ activators. Nature. 1998 Jun 25;393(6687):790-3.

2.F Sullivan AC, Triscari J. Metabolic regulation as a control for lipid disorders. I. Influence of (-)-hydroxycitrate on experimentally induced obesity in the rodent. American Journal of Clinical Nutrition 1977;30:767-775.

Robert Fog

5/9/06

LIST OF PRIOR ART CITED BY APPLICANT

Sheet 3 of 3

Dallas L. Clouatre

(-)-HYDROXYCITRIC ACID FOR CONTROLLING INFLAMMATION

July 2, 2003

Enf
Sullivan, Ann C. and Joseph Triscari. Possible interrelationship between metabolite flux and appetite. In D. Novin, W. Wyriwicka and G. Bray, eds., Hunger: Basic Mechanisms and Clinical Implications (New York: Raven Press, 1976) 115-125.

Sullivan AC, Gruen RK. Mechanisms of appetite modulation by drugs. Federation Proceedings 1985;44,1:139-144.

Enf
Thomas SR, et al. Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):585-93.

Zebrak Fay

5/29/06